RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Targeting drug tested for Tough-to-Treat blood cancers
Disease control OngoingThis is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug duo tested in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or hasn't responded to other treatments. The goal is to see if this combination can help control the cancer. The stud…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug duo tested to fight aggressive blood cancer
Disease control OngoingThis study is testing a combination of two drugs, pembrolizumab and romidepsin, for people with a type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if using these drugs together is safe and mor…
Matched conditions: RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC